Clinical trials: HPV Infection, open to volunteers
HPV-induced Cancers, HPV Infections
Tolerance and Effectiveness of C14 on HPV Infection
The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV.
- Conditions
- HPV-induced Cancers, HPV Infections, HIV, Cervical Cancers
- Trial name
- PREPAP (NCT06672653)
- Testing
- The monoterpenoid zinc tetra-ascorbo-camphorate ("C14"), Distilled water group
- Where
- Democratic Republic of the Congo
- Volunteers
- 66 people
- Sponsor
- MGB Pharma
HPV Infection, CIN 2/3
Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden.
- Conditions
- HPV Infection, CIN 2/3, Cervical Cancer
- Trial name
- NCT04910802
- Testing
- Gardasil9
- Where
- Sweden
- Volunteers
- 150,000 people
- Sponsor
- Miriam Elfström
Cervical Cancer Screening, HPV Infection
Risk of Cervical Cancer Following Incident, Persistent and History-unknown HPV Detection
The goal of this register-based retrospective observational study is to understand the risk of cervical cancer following incident, persistent and history-unknown HPV detection by HPV genotype in healthy women participating in…
- Trial name
- NCT07850128
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 130,000 people
- Sponsor
- Karolinska Institutet
HPV Infection, Preventive Health Services
PCOM2 - The Physician Communication Intervention, Version 2.0
Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases.
- Trial name
- PCOM2 (NCT05336240)
- Testing
- Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
HPV 16 Infection, HPV-Related Carcinoma
Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection
This healthy related donor clinical trial is linked to a recipient clinical trial protocol for therapeutic purposes. In this healthy donor protocol, haploidentical relatives of a patient with recurrent or metastatic human…
- Conditions
- HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
- Trial name
- J21112LINKED (NCT06508138)
- Testing
- pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Cancer, HPV Infection
Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening
This study is testing and implementing an equity-focused, community-based intervention that improves women's access to cervical cancer screening and adherence to follow up after an abnormal result.
- Trial name
- NCT07453459
- Testing
- Qualitative Interview, Virtual Visit Standard Instructions, Virtual Visit Standard Instructions + In-Person Registration Navigation
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
HIV Infections, HPV Infection
Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya
This randomized, placebo-controlled trial will evaluate self-administered 5-fluorouracil (5FU) to improve human papillomavirus (HPV) clearance after thermal ablation (TA) in Women With Human Immunodeficiency Virus (HIV) (WWH) in…
- Conditions
- HIV Infections, HPV Infection, Cervix Cancer, CIN2
- Trial name
- ASCEND (NCT07545746)
- Testing
- 5% 5-fluorouracil Topical Cream
- Where
- 2 sites in Kenya
- Volunteers
- 140 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cervical Cancer, Cervical Dysplasia
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring.
- Conditions
- Cervical Cancer, Cervical Dysplasia, Oropharyngeal Cancer, Human Papillomavirus Infection
- Trial name
- NCT05774561
- Testing
- Arm A - Diagnostic test: HPV detection in liquid biopsies, Arm B - Diagnostic test: HPV detection in liquid biopsies
- Where
- Czechia
- Volunteers
- 480 people
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
Cervical Cancer, Papilloma Viral Infection
Reducing Urban Cervical Cancer Disparities
This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention.
- Trial name
- NCT06416150
- Testing
- Stage 1 SOC, Stage 1 HERS, Stage 2 HERS
- Where
- 3 sites in United States
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Background: Recurrent respiratory papillomatosis (RRP) is a rare disease that causes wart-like growths called papillomas to grow in the airway, most often in the voice box, windpipe, or lungs.
- Conditions
- Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV), Papillomavirus Infection, Laryngeal Diseases
- Trial name
- NCT07756840
- Testing
- PRGN-2012, Bevacizumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Warts
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for…
- Trial name
- NCT05625633
- Testing
- Human Papillomavirus 9-valent Vaccine, Recombinant, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Western Institute for Veterans Research
HPV-Related Carcinoma, HPV Infection
Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.
The primary aim of the study is to determine the total risk of AIN in group of HPV-RGD survivors and additionally to establish an exact risk for each of HPV-related gynecological precancers/cancers.
- Trial name
- NCT06574087
- Testing
- hrHPV test and cytology
- Where
- Poland
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- PCK Marine Hospital in Gdynia
Cervical Cancer, Vulvar Cancer
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT04422366
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Cervical Carcinoma, Vaginal Carcinoma
HPV Vaccine, Imiquimod, and Metformin Combination Trial
The goal of this clinical trial is to explore whether additional treatments can help strengthen the participant's immune system to fight cancer caused by the Human Papillomavirus (HPV), a virus spread through intimate…
- Conditions
- Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
- Trial name
- HPV-VIM (NCT06686043)
- Testing
- HPV vaccine, Imiquimod, and metformin combination therapy
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Baylor College of Medicine
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
The goal of this clinical study is to learn if DARE-HPV can treat persistent high-risk human papillomavirus (hrHPV). The primary outcome will be if the genital infection clears following treatment in 30, 60 or 90 days.
- Trial name
- NCT07601074
- Testing
- Lopinavir / ritonavir
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Daré Bioscience, Inc.
High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women.
- Conditions
- High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion, ASC-US, HPV Infection
- Trial name
- NCT07572396
- Testing
- EGCG and Quinine Sulfate Vaginal Suppository
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- Amplexd Therapeutics, Inc.
Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Background: Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and…
- Conditions
- Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis, Warts
- Trial name
- NCT00867269
- Where
- United States
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Human Papillomavirus-Related Cervical Carcinoma
Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
Background In sub-Saharan Africa (SSA), human papillomavirus (HPV) and HIV create a dual burden of disease that causes significant morbidity and mortality in the form of cervical cancer (CC).
- Conditions
- HIV Infection, Human Papillomavirus-Related Cervical Carcinoma, Screening Strategy
- Trial name
- NCT06708351
- Testing
- Best Practice, Health Promotion and Education, HPV Self-Collection
- Where
- Kenya
- Volunteers
- 2,280 people, healthy volunteers welcome
- Sponsor
- Emory University
Cervical Carcinoma, Human Papillomavirus Infection
Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening
This clinical trial evaluates whether offering human papillomavirus (HPV) self-collection for cervical cancer screening at Mayo Clinic Express Care clinics improves uptake of cervical cancer screening and receipt of appropriate…
- Conditions
- Cervical Carcinoma, Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
- Trial name
- NCT07186530
- Testing
- Best Practice, Communication Intervention, Electronic Health Record Review
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic